Tag: Pharmaceutical industry

The global analgesics market is projected to reach over USD 92 billion in 2025 [1.5.1, 1.5.6]. The question 'Is Cadila a painkiller?' highlights a frequent confusion between a drug's brand or manufacturer and the medication itself. Cadila Pharmaceuticals is a key manufacturer, not a single drug.

In 2023, the U.S. Food and Drug Administration (FDA) saw 1,296 pharmaceutical recalls, a number that highlights the ongoing challenges in drug quality and safety. Understanding the answer to 'How many drugs does the FDA recall every year?' reveals a complex system designed to protect public health.

First approved by the FDA in 2010, the medication known as VPRIV was originally manufactured by Shire plc. This article details the complex manufacturing history of VPRIV, explaining how it transitioned from its original developer to being produced by Takeda Pharmaceuticals today.

Founded as Columbus Pharmacal in 1885, Roxane Laboratories was a prominent U.S. generic drug manufacturer for decades before its acquisition in 2016 by Hikma Pharmaceuticals. To understand what is Roxane medicine, one must look at the legacy of this former company and the specific medications it produced, rather than a single drug.

Originally synthesized in Germany in 1916, oxycodone was later patented in the U.S. by Purdue Pharma, but today, multiple companies manufacture this opioid pain reliever. Understanding **who makes oxycodone** reveals a complex history involving brand-name drugs and a shift toward a market dominated by generic alternatives.

In 2022, over $25 billion in biopharmaceutical exports were from majority foreign-owned firms operating in the United States, highlighting the significant role international investment plays in the industry. This multifaceted financial landscape reveals that answering the question of who owns US pharma is far from straightforward, involving a mix of institutional, public, foreign, and venture capital ownership.

In the complex and jargon-filled pharmaceutical industry, the acronym DSI can refer to at least five different concepts, from drug safety to digital genomics. Understanding **what is DSI in pharmaceutical?** is crucial for navigating specific sectors like drug development, regulatory affairs, or digital health.

According to the American Society of Health-System Pharmacists (ASHP), the United States saw a record number of active drug shortages in the first quarter of 2024, highlighting the urgency of understanding the so-called “drug exodus”. This informal term describes the significant, large-scale movements and challenges within the pharmaceutical landscape, including the discontinuation of vital medications and shifts in drug abuse patterns.

The global pharmaceutical ERP market is projected to reach $3.71 billion by 2027. A key driver of this growth is SAP (Systems, Applications, and Products), an enterprise resource planning (ERP) software that streamlines and integrates core business processes. So, **what is SAP in pharmacy?** It's the digital backbone for managing operations.

In 2019, over 112 million prescriptions were written for Atorvastatin, making it one of the most prescribed drugs in the US [1.3.1]. When asking, 'What are the big 3 drugs?', the answer depends entirely on the metric: sales, prescription volume, or historical importance.